Xenopat SL

Xenopat SL is an SME in Hospitalet de Llobregat, Spain that has taken part in 6 EU-funded projects since 2017, receiving €630k in EU funding.

EU funding received€630k
EU projects6
As coordinator0
Running now2
First EU project2017
Latest project2025
CountrySpain
EU registration (PIC)933964695
On this page · 5 sections→

Where the EU money came from

Funding by EU programme. Amounts are Xenopat SL's own share of each project, not the project's full budget.

  • Horizon 2020€612k · 5 projects
  • Horizon Europe€18k · 1 project

Projects

6 EU-funded projects, newest first. Each links to the official record.

  • EVERESTPartner

    Extracellular Vesicle Research Exchanges for Advanced Biomarkers and Therapeutics

    Horizon Europe · 2025–2028 · Project on CORDIS ↗

    €18ktheir share
  • PERSIST-SEQPartner

    Building a reproducible single-cell experimental workflow to capture tumour cell persistence

    Horizon 2020 · 2021–2027 · Project on CORDIS ↗

    €323ktheir share
  • CRYSTAL3Partner

    Commercial & Research Opportunity for Cysteinyl Leukotriene Signalling in Ocular & CNS Dysfunction, Cancer and Cardiovascular Disease

    Horizon 2020 · 2021–2024 · Project on CORDIS ↗

    €133ktheir share
  • cONCReTEPartner

    DevelOpmeNt of Cancer RNA TherapEutics

    Horizon 2020 · 2020–2025 · Project on CORDIS ↗

    €110ktheir share
  • EPIPHARMPartner

    Development of a ncRNA DNA Methylation Kit for Treatment Guidance in Cancer of Unknown Primary

    Horizon 2020 · 2017–2018 · Project on CORDIS ↗

    €30ktheir share
  • 3D NEONETPartner

    Drug Discovery and Delivery NEtwork for ONcology and Eye Therapeutics

    Horizon 2020 · 2017–2022 · Project on CORDIS ↗

    €15ktheir share

Works most with

Organisations that shared the most EU projects with this one. A good starting list for consortium partners.

Fields it works in

Research fields recorded on its Horizon projects.

  • DNA
  • RNA
  • breast cancer
  • cardiovascular diseases
  • cell biology
  • drug allergy
  • drug discovery
  • epigenetics
  • gene therapy
  • molecular biology
  • oncology
  • personalized medicine
  • prostate cancer
  • retinopathy

Is this your organisation?

Claim it with an EUACC listing (€39 once, reviewed by our editors): add what you build, your team and what you are looking for. We pre-fill it from your EU records. Listed companies reach investors through our newsletter and get matched to new EU calls first.

Claim this profile →

Source: CORDIS (Horizon Europe, Horizon 2020, FP7) and the EU Funding & Tenders Portal (other EU programmes), matched by the EU registration number (PIC). Past participation does not mean the organisation is open to new partnerships.

Europe’s tech funding.
One place.

The weekly briefing

Funding calls, VC news and key deadlines — a weekly briefing for European founders.

Free · unsubscribe anytime